Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors

AIDS

Volumn 13, Issue 13, 1999, Pages 1623-1627

  Profit, Louise ^b   Eagling, Victoria A ^b   Back, David J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NONE

Author keywords

Caco 2 cells; Lymphocytes; P glycoprotein; Protease inhibitor; Rhodamine 123; Saquinavir

Indexed keywords

GLYCOPROTEIN P; INDINAVIR; KETOCONAZOLE; NELFINAVIR; PROTEINASE INHIBITOR; RHODAMINE 123; RITONAVIR; SAQUINAVIR; VERAPAMIL;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG POTENCY; DRUG TRANSPORT; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; LYMPHOCYTE; MEMBRANE PERMEABILITY; MONOLAYER CULTURE; PRIORITY JOURNAL;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; FLOW CYTOMETRY; FLUORESCENT DYES; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LYMPHOCYTES; NELFINAVIR; P-GLYCOPROTEIN; RHODAMINE 123; RITONAVIR; SAQUINAVIR; TEMPERATURE; VERAPAMIL;

EID: 0033371825     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199909100-00004     Document Type: Article

References (16)

1. Perry C, Noble S. Saquinavir soft gel capsule formulation. Drugs 1998, 53:461-486.
2. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small intestinal cytochrome P-450. Drug Metab Dispos 1997, 25:256-267.
3. Eagling VE, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997, 44:190-194.
4. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
5. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 1995, 13:129-134.
6. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localisation of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987, 84:7735-7738.
7. Hunter J, Jepson MA, Tsuruo T, et al. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J Biol Chem 1993, 268:14991-14997.
8. Alsenz J, Steffen H, Rainer A. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monalayers. Pharm Res 1998, 15:423-428.
9. Hoetelmans RMW. Sanctuary sites in HIV-1 infection. Antiviral Ther 1998, 3:13-17.
10. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992, 11:2735-2739.
11. Lee CGL, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998, 37:3594-3601.
12. Andreana A, Aggarwal S, Gollapudi S, et al. Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1996, 12:1457-1462.
13. Isuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41:1967-1972.
14. Siegsmund MJ, Cardarelli C, Aksentijevich I, et al. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 1994, 151:485-491.
15. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
16. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients, AIDS 1997, 11:F117-F120.